Mouse Models of Mucormycosis.
Dissemination
Immunosuppression
Intranasal application
Intratracheal application
Ketoacidosis
Lichtheimia
Mucor
Rhizopus
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
8
5
2023
pubmed:
5
5
2023
entrez:
5
5
2023
Statut:
ppublish
Résumé
Animal models have been crucial in understanding the pathogenesis and developing novel therapeutic approaches for fungal infections in general. This is especially true for mucormycosis, which has a low incidence but is often fatal or debilitating. Mucormycoses are caused by different species, via different routes of infections, and in patients differing in their underlying diseases and risk factors. Consequently, clinically relevant animal models use different types of immunosuppression and infection routes.This chapter describes how to induce different types of immunosuppression (high dose corticosteroids and induction of leukopenia, respectively) or diabetic ketoacidosis as underlying risk factors for mucormycosis. Furthermore, it provides details on how to perform intranasal application to establish pulmonary infection. Finally, some clinical parameters that can be used for developing scoring systems and define humane endpoints in mice are discussed.
Identifiants
pubmed: 37145285
doi: 10.1007/978-1-0716-3199-7_14
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-196Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Binder U, Maurer E, Lass-Flörl C (2014) Mucormycosis--from the pathogens to the disease. Clin Microbiol Infect 20(Suppl 6):60–66. https://doi.org/10.1111/1469-0691.12566
doi: 10.1111/1469-0691.12566
pubmed: 24476149
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP (2012) Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 54(Suppl 1):S23–S34. https://doi.org/10.1093/cid/cir866
doi: 10.1093/cid/cir866
pubmed: 22247442
Gomes MZ, Lewis RE, Kontoyiannis DP (2011) Mucormycosis caused by unusual mucormycetes, non-Rhizopus, −Mucor, and -Lichtheimia species. Clin Microbiol Rev 24(2):411–445. https://doi.org/10.1128/CMR.00056-10
doi: 10.1128/CMR.00056-10
pubmed: 21482731
pmcid: 3122490
Lewis RE, Kontoyiannis DP (2013) Epidemiology and treatment of mucormycosis. Future Microbiol 8(9):1163–1175. https://doi.org/10.2217/fmb.13.78
doi: 10.2217/fmb.13.78
pubmed: 24020743
Hassan MIA, Voigt K (2019) Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Med Mycol 57(Supplement_2):S245–S256. https://doi.org/10.1093/mmy/myz011
doi: 10.1093/mmy/myz011
pubmed: 30816980
pmcid: 6394756
Kronen R, Liang SY, Bochicchio G, Bochicchio K, Powderly WG, Spec A (2017) Invasive fungal infections secondary to traumatic injury. Int J Infect Dis 62:102–111. https://doi.org/10.1016/j.ijid.2017.07.002
doi: 10.1016/j.ijid.2017.07.002
pubmed: 28705753
Garcia-Hermoso D, Criscuolo A, Lee SC, Legrand M, Chaouat M, Denis B, Lafaurie M, Rouveau M, Soler C, Schaal JV, Mimoun M, Mebazaa A, Heitman J, Dromer F, Brisse S, Bretagne S, Alanio A (2018) Outbreak of invasive wound Mucormycosis in a burn unit due to multiple strains of Mucor circinelloides f. circinelloides resolved by whole-genome sequencing. mBio 9(2). https://doi.org/10.1128/mBio.00573-18
Kyriopoulos EJ, Kyriakopoulos A, Karonidis A, Gravvanis A, Gamatsi I, Tsironis C, Tsoutsos D (2015) Burn injuries and soft tissue traumas complicated by mucormycosis infection: a report of six cases and review of the literature. Ann Burns Fire Disasters 28(4):280–287
pubmed: 27777549
pmcid: 5068897
Struck MF, Gille J (2013) Fungal infections in burns: a comprehensive review. Ann Burns Fire Disasters 26(3):147–153
pubmed: 24563641
pmcid: 3917146
Lelievre L, Garcia-Hermoso D, Abdoul H, Hivelin M, Chouaki T, Toubas D, Mamez AC, Lantieri L, Lortholary O, Lanternier F (2014) Posttraumatic mucormycosis: a nationwide study in France and review of the literature. Medicine 93(24):395–404. https://doi.org/10.1097/md.0000000000000221
doi: 10.1097/md.0000000000000221
pubmed: 25500709
pmcid: 4602436
Kaur H, Ghosh A, Rudramurthy SM, Chakrabarti A (2018) Gastrointestinal mucormycosis in apparently immunocompetent hosts-A review. Mycoses 61(12):898–908. https://doi.org/10.1111/myc.12798
doi: 10.1111/myc.12798
pubmed: 29855116
Mitchell SJ, Gray J, Morgan ME, Hocking MD, Durbin GM (1996) Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors. Lancet 348(9025):441–443
doi: 10.1016/S0140-6736(96)05059-3
pubmed: 8709784
Pana ZD, Seidel D, Skiada A, Groll AH, Petrikkos G, Cornely OA, Roilides E (2016) Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis 16(1):667. https://doi.org/10.1186/s12879-016-2005-1
doi: 10.1186/s12879-016-2005-1
pubmed: 27832748
pmcid: 5105268
Corzo-Leon DE, Chora-Hernandez LD, Rodriguez-Zulueta AP, Walsh TJ (2018) Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol 56(1):29–43. https://doi.org/10.1093/mmy/myx017
doi: 10.1093/mmy/myx017
pubmed: 28431008
Spellberg B, Edwards J Jr, Ibrahim A (2005) Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 18(3):556–569. https://doi.org/10.1128/CMR.18.3.556-569.2005
doi: 10.1128/CMR.18.3.556-569.2005
pubmed: 16020690
pmcid: 1195964
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, Chen SC (2019) The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect 25(1):26–34. https://doi.org/10.1016/j.cmi.2018.07.011
doi: 10.1016/j.cmi.2018.07.011
pubmed: 30036666
Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikkos G (2011) Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 17:1859. https://doi.org/10.1111/j.1469-0691.2010.03456.x
doi: 10.1111/j.1469-0691.2010.03456.x
pubmed: 21199154
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 5:634–653. CID36019 [pii]. https://doi.org/10.1086/432579
doi: 10.1086/432579
Van Cutsem J, Fransen J, Janssen PA (1988) Experimental zygomycosis due to Rhizopus spp. infection by various routes in Guinea-pigs, rats and mice. Mycoses 31(11):563–578
doi: 10.1111/j.1439-0507.1988.tb04410.x
pubmed: 3216879
Ibrahim AS (2014) Host-iron assimilation: pathogenesis and novel therapies of mucormycosis. Mycoses 57(Suppl 3):13–17. https://doi.org/10.1111/myc.12232
doi: 10.1111/myc.12232
pubmed: 25178879
pmcid: 4461208
Balloy V, Huerre M, Latge JP, Chignard M (2005) Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 73(1):494–503
doi: 10.1128/IAI.73.1.494-503.2005
pubmed: 15618189
pmcid: 538925
Philippe B, Ibrahim-Granet O, Prevost MC, Gougerot-Pocidalo MA, Sanchez Perez M, Van der Meeren A, Latge JP (2003) Killing of aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates. Infect Immun 71(6):3034–3042
doi: 10.1128/IAI.71.6.3034-3042.2003
pubmed: 12761080
pmcid: 155721
Jacobsen ID (2019) Animal models to study Mucormycosis. J Fungi (Basel) 5(2):27. https://doi.org/10.3390/jof5020027
doi: 10.3390/jof5020027
pubmed: 30934788
Dos Santos AR, Fraga-Silva TF, de Fátima A-DD, Dos Santos RF, Finato AC, Soares CT, Lara VS, Almeida NLM, Andrade MI, de Arruda OS, de Arruda MSP, Venturini J (2022) IFN-γ mediated signaling improves fungal clearance in experimental pulmonary Mucormycosis. Mycopathologia 187(1):15–30. https://doi.org/10.1007/s11046-021-00598-2
doi: 10.1007/s11046-021-00598-2
pubmed: 34716549
Dos Santos AR, Fraga-Silva TF, Almeida DF, Dos Santos RF, Finato AC, Amorim BC, Andrade MI, Soares CT, Lara VS, Almeida NL, de Arruda OS, de Arruda MS, Venturini J (2020) Rhizopus-host interplay of disseminated mucormycosis in immunocompetent mice. Future Microbiol 15:739–752. https://doi.org/10.2217/fmb-2019-0246
doi: 10.2217/fmb-2019-0246
pubmed: 32686962
Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Najvar LK, Patterson TF, Filler SG, Ibrahim AS (2021) Evaluation of sex differences in murine diabetic ketoacidosis and neutropenic models of invasive mucormycosis. J Fungi (Basel) 7 (4):313. doi:10.3390/jof7040313
Ogino MH, Tadi P (2022) Cyclophosphamide. In: StatPearls (ed) StatPearls Publishing Copyright © 2022. StatPearls Publishing LLC, Treasure Island (FL)
Ahlmann M, Hempel G (2016) The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol 78(4):661–671. https://doi.org/10.1007/s00280-016-3152-1
doi: 10.1007/s00280-016-3152-1
pubmed: 27646791
Allen IC (2014) The utilization of oropharyngeal intratracheal PAMP administration and bronchoalveolar lavage to evaluate the host immune response in mice. J Vis Exp 86:51391. https://doi.org/10.3791/51391
doi: 10.3791/51391
Ullman-Culleré MH, Foltz CJ (1999) Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci 49(3):319–323
pubmed: 10403450
Diehl R, Ferrara F, Müller C, Dreyer AY, McLeod DD, Fricke S, Boltze J (2017) Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol 14(2):146–179. https://doi.org/10.1038/cmi.2016.39
doi: 10.1038/cmi.2016.39
pubmed: 27721455
Martins TG, Gama JB, Fraga AG, Saraiva M, Silva MT, Castro AG, Pedrosa J (2012) Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection. PLoS One 7(2):e32740. https://doi.org/10.1371/journal.pone.0032740
doi: 10.1371/journal.pone.0032740
pubmed: 22393444
pmcid: 3290623